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Abstract  
Introduction: We present practical metrics for estimating the expected health benefits of specific 
research proposals. These can be used by research funders, researchers, and health-care decision 
makers within low- and middle-income countries (LMICs) to support evidence-based research 
prioritisation. 
Methods: The methods require three key assessments: (1) the current level of uncertainty around 
the endpoints the proposed study will measure; (2) how uncertainty impacts on the health benefits 
and costs of health-care programmes; and (3) the health opportunity costs imposed by programme 
costs. Research is valuable because it can improve health by informing the choice of which 
programmes should be implemented. We provide a Microsoft Excel tool to allow readers to 
generate estimates of the health benefits of research studies based on these three assessments. The 
tool can be populated using clinical studies, existing cost-effectiveness models and expert opinion. 
Where such evidence is not available, the tool can quantify the value of research under different 
assumptions. Estimates of the health benefits of research can be considered alongside research 
costs, and the consequences of delaying implementation until research reports, to determine 
whether research is worthwhile. We illustrate the method using a case study of research on HIV self-
testing programmes in Malawi. This analysis combines data from the literature with outputs from 
the HIV synthesis model.  
Results: For this case study we found a costing study that could be completed and inform decision 
making within one year offered the highest health benefits (67,000 DALYs averted). Research on 
outcomes improved population health to a lesser extent (12,000 DALYs averted) and only if carried 
out alongside programme implementation.  
Conclusion: Our work provides a method for estimating the health benefits of research in a practical 
and timely fashion. This can be used to support accountable use of research funds. 
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Summary box  
What is already known? 
x Methods are available to estimate the value of research studies but are not widely understood, 
appreciated or applied.  
What are the new findings? 
x We provide a method and companion Microsoft Excel tool that can be used to estimate the 
health benefits of research studies without using advanced value of information methods. 
x The tool can be populated using a range of evidence or used to test how different assumptions 
affect the value of research.  
x We illustrate the method by applying it to estimate the value of research studies on HIV self-
testing programmes. 
What do the new findings imply? 
x Our work provides a method for estimating the health benefits of research in a practical and 
timely fashion; these estimates can be considered alongside research costs to prioritise 
research studies for funding. 
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INTRODUCTION 
Globally, significant resource and effort is spent on health-related research with the 10 largest public 
and philanthropic funders spending US $37.1 billion in 2013.(1) An important component of this 
funding is dedicated to basic science and preclinical research. However, much research aims to 
better understand current epidemiological patterns, health care provision and patient outcomes, 
and how they would be impacted by alternative interventions with a view to informing health care 
investments in the near-term. Clinical trials, surveillance programmes, cost studies, morbidity 
surveys and implementation studies all serve this purpose.  By improving the information available 
to support investment decisions, they have the potential to improve population health. However, 
research is costly and those funding research have constraints on their ability to expand research 
budgets. This raises the question of which research activities should be prioritised.  
To answer this question there is a need to understand why evidence is valuable to health care 
systems and the populations they serve, and how to assess the value of specific research proposals. 
This has been recognised by a number of stakeholders and a set of methods called value of 
information analysis allow the value of specific research proposals to be quantified.(2-4) Value of 
information analyses have been applied in a range of contexts in high-income settings, for example 
to assess the value of clinical trials of interventions for which limited evidence exists.(5, 6) Previous 
studies have also estimated the value of further research in low- and middle-income country (LMIC) 
settings.(4, 7, 8) These studies used advanced methods (4, 7, 8) that require specific types of 
analyses to have been conducted (probabilistic analyses of a model already addressing the policy 
question of interest)(9, 10). The application of value of information analyses to help prioritise 
research has therefore been limited as the advanced methods required are often not practical given 
time and resource constraints, and computation may be impractical where transmission models are 
required to represent disease dynamics. 
In this paper we use a graphical method and simple metrics to show how the principles of value of 
information analysis can be applied in these common but challenging circumstances. We provide a 
simple excel tool to facilitate use of the method and explain how the method can be applied using 
different types of evidence including typical outputs from existing cost-effectiveness models. We 
also discuss how this type of analysis can inform key policy questions relating to the allocation of 
research funds. We then apply this method in a case study assessing the value of research in HIV 
self-testing programmes in Malawi. 
The methods presented are relevant to any party with a stake in ensuring health research funds are 
used in a way that is expected to improve population health. This includes research funders, 
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researchers, and health-care decision makers within LMICs who rely on robust evidence to make 
investment decisions. The latter group includes individuals within ministries of health charged with 
prioritising health programmes (including designing health benefits packages), and other decision 
makers at a regional and national level who are responsible for health care resource allocation. The 
methods presented apply where a single budget is used to fund research and service provision, and 
to the more common situation where budgets for these activities are separate.   
 
METHODS 
Graphical illustration using a simple quantitative tool to quantify the value of research  
Cost-effectiveness analyses are routinely used to assess whether a programme is expected to 
improve population health once the health opportunity costs imposed by additional programme 
spending are accounted for. This assessment can be summarised using an estimate of the net 
disability adjusted life years (DALYs) averted by the programme. This reflects both the health 
benefits of the programme and an assessment of the health forgone as funding a programme means 
that resources will be unavailable for the delivery of other programmes. This is calculated as the 
DALYs directly averted via the programme minus the DALYs forgone elsewhere in the health system 
due to the additional programme funding required.  
In the same way we can quantify the net DALY impact of investing in health care provision, we can 
also quantify the net DALY impact of investing in research. This idea is the basis for value of 
information analysis. 
To assess the value of a research study or other data collection or evidence gathering activities, we 
need to understand the types of uncertainty that we could examine in a study with particular 
endpoints. These endpoints may be epidemiological, clinical, patient-reported, process-related or 
economic. For example, we might be uncertain about the effectiveness of a drug, the uptake of a 
rural community-based prevention programme, the quality of life of people with different treatment 
outcomes, or the cost of implementing a new diagnostic pathway. To assess the value of improving 
information relating to an endpoint we need to understand our current level of uncertainty about 
the endpoint given existing evidence. This uncertainty can be described by a probability distribution 
showing the likelihood that the endpoint takes different values. This distribution is often called a 
prior, since it is based on existing knowledge of uncertainty about the specific endpoint. Figure 1 
Panel B shows the prior on an uncertain endpoint as a histogram.  
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Uncertainty about the endpoint alone is not sufficient to justify expenditure on research. For 
research to deliver value, the uncertainty in the endpoint must translate to uncertainty about 
whether the programme is cost-effective. For example, we might be highly uncertain about a 
ƉƌŽŐƌĂŵŵĞ ?Ɛ effects on clinical outcomes. However, if the programme is cost-effective across the 
range of plausible clinical outcomes then further research on this endpoint would not deliver value 
in this setting as it would not change the decision about funding the intervention. 
We can assess whether uncertainty in the endpoint is likely to translate to uncertainty about cost-
effectiveness by estimating the net DALYs we would expect to avert if the endpoint was found to 
take the different values reflected in the prior. This is shown in Figure 1 Panel A. In this illustration, 
as the endpoint increases, the net DALYs averted increase. This reflects estimates of how both DALYs 
averted and additional costs (or cost savings) change with the value of the endpoint. It also reflects a 
measure of the health opportunity cost of financing the programme, as this allows the additional 
costs of the programme to be converted to health foregone.  
The mean value of the endpoint represents our  “ďĞƐƚŐƵĞƐƐ ?of the value the endpoint takes given 
currently available information. At this value the net DALYs averted by the programme are positive 
and the programme would be considered cost effective. However, below a certain  “trigger ? value of 
the endpoint, the net health effects of the programme become negative i.e. the programme is not 
cost-effective. The shaded area of the prior histogram (Figure 1 Panel B) indicates the probability 
that the endpoint will fall below the trigger point. This is the probability that the intervention will 
turn out not to be cost-effective and that implementation will reduce population health. However, if 
we conduct research to improve our understanding of the endpoint this is the probability that the 
research could change the implementation decision.  If it is considered implausible that the endpoint 
could take a value as extreme as the trigger point then further research will not result in a change in 
decision and, therefore, should not be conducted in this setting as it would represent a waste of 
resources.  This emphasises that we should care about uncertainty in endpoints when it leads to 
uncertainty in decisions.  
Without additional research, on average implementation averts DALYs but if low values of the 
endpoint are realised, implementation reduces population health. If research is conducted and 
indicates that the endpoint falls below the trigger point at which the programme is not cost-
effective, then the programme will not be implemented. Research therefore avoids the health losses 
associated with programme implementation under these conditions as shown by the grey bars in 
Figure 1 Panel A. These bars therefore represent the potential health gains from research. The 
expected net DALYs averted via research are calculated as the health gains (resulting from avoided 
health losses) when the endpoint takes values below the trigger point i.e., the shaded bars in Figure 
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1 Panel A weighted by the probability of the quantity taking each value below the trigger point i.e., 
the shaded bars in Figure 1 Panel B.  
Figure 1 Panel C and D show how the value of research can be calculated when the programme is 
not expected to be cost-effective based on current information. Without further research the 
programme is not implemented and no population health gains are generated. With further 
research, there is a possibility that the endpoint will take values sufficiently high to support 
implementation and net DALYs are averted. The possible health gains from research are again shown 
by the grey bars (Figure 1 Panel C).   
This method shows the value of completely eliminating the uncertainty around the endpoint. 
Although in reality further research will not resolve all uncertainty, the estimates generated provide 
an expected upper bound for the population health benefits from research for the setting of 
interest.    
 
Figure 1: Calculating the net health effects of research 
Legend: Panel A shows net DALYs averted by the programme for different values of the endpoint of 
interest when the programme  is expected to be cost-effective based on current evidence; Panel B 
and D show the prior on the uncertain endpoint; Panel C shows net DALYs averted by the programme 
for different values of the endpoint of interest when the programme  is not expected to be cost-
effective based on current evidence. 
 
We express the value of the research proposals using two different metrics. The first is the net DALYs 
averted by using the research to improve decision making. Where a research study is expected to be 
used in a number of countries, the approach described above can be applied for each country and 
the net DALYs averted across countries can be calculated.  Individual country estimates of the net 
DALYs averted by research are likely to differ for a range of reasons including differences in the size 
of the population that stand to benefit from research, the costs and health benefits of the 
programme and the health opportunity costs of health care funds. 
The net DALYs averted by research provides an estimate of the expected maximum population health 
gains from research accounting for both health gains and programme costs, but  it does not consider 
research costs. Funding a specific research proposal has opportunity costs, which are the health gains 
that could be generated by using this funding for other research studies.  
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The second metric is therefore the maximum amount a research funder should be willing to spend 
on the research, given its estimated net health effects. This metric is estimated by multiplying the 
net DALYs averted by research by a measure of the opportunity cost of research funds. We assume 
that research funds have similar levels of opportunity costs as funds for service provision. For 
example, if a research study is expected to avert 1,000 DALYs and our measure of opportunity costs 
indicates that every $500 of expenditure reduces outcomes elsewhere in the health system by 1 
DALY, then the maximum a research funder should be willing to spend on the research would be 
$500,000. If they spend more than this the health opportunity costs of funding the research would 
exceed 1,000 DALYs and thus, more than outweigh the net health gains from research. Given the 
very different sources of funding that typically underpin service provision and research, the 
opportunity cost of research funds may differ from the opportunity cost of service funding. We will 
return to the question of how the opportunity cost of research funds could be estimated in the 
discussion.  
To illustrate the approach, we use a numeric example where we are interested in an outcomes 
endpoint that can, in principle, take different values between 0 and 1 (for example, the probability of 
treatment response). Our existing knowledge of the endpoint indicates it is expected to take a value 
of 0.10 (standard error 0.04, 95% confidence interval 0.04, 0.19), which allows us to define its the 
prior1.  In a second step, we make use of existing information about how different values of the 
endpoint influence health effects and costs of the programme. In the present example, we know that 
if the endpoint takes the average value, the programme is expected to avert 2,000 DALYs. If the 
endpoint takes the value at the lower bound of the confidence interval the programme is expected to 
avert 1,000 DALYs, whereas if the endpoint takes the value at the higher bound of the confidence 
interval, the programme is expected to avert 3,000 DALYs. The expected additional long-term costs 
associated with the programme is $450,000 and is not expected to vary with the endpoint. Lastly, we 
evaluate the health opportunity cost associated with funding the intervention. This is 1,500 DALYs 
based on additional costs of $450,000 and an estimate of health opportunity cost of $300/DALY. This 
information about the DALYs averted at different values of the endpoint, and about opportunity costs, 
allows us to estimate the net DALYs averted at different values of the endpoint. We provide a simple 
excel tool to allow users to review the numeric example and apply the approach to their own contexts 
(see supplementary material). The tool provides a graphical summary of the prior information and the 
relationship between net health effects and the endpoint of interest as shown in Figure 2.  
                                                             
1 We apply a beta distribution here. 
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The tool uses regression methods to generate estimates of the net health effects of a programme at 
all plausible values of the endpoint. The regression uses estimates of DALYs averted and additional 
costs at different values of the endpoint that are entered by the user. Two regressions are then 
fitted, one regressing DALYs averted on the endpoint and the other regressing additional costs on 
the endpoint. Options are available to use linear regression, or to assume range of non-linear 
relationships between the endpoint and DALYs averted or additional costs.   
The tool uses the data entered to generate estimates of the benefits of research. The tool shows the 
implications of making decisions based on current evidence, and the potential benefits of making 
decisions on the basis of further research as shown in Figure 2. Without further research we can only 
base our decision on what we expect to occur. We expect that the programme averts 1,8682 DALYs 
with a health opportunity cost of 1,500 DALYs i.e. 368 net DALYs averted. On this basis, we 
implement the programme based on current evidence. If we conduct research we will gain more 
information about which value the endpoint takes. If the outcome is as expected or higher, there is 
no change to the decision. If the outcome endpoint is lower than the trigger point of 0.07, the net 
DALYs averted become negative and we choose not to implement the intervention. Weighting the 
probability of observing values of the endpoint below 0.07 by the net DALYs averted by avoiding 
implementation, we expect the research to avert 59 DALYs. If the research is only considered 
relevant in this context then the maximum a research funder should be willing to spend on the 
research is $17,800, suggesting that this may not be a high priority area for research. If the research 
is expected to inform decision-making in other countries, then the process can be repeated for each 
country, and the value of research across countries can be calculated. 
 
Figure 2: Output of quantitative excel tool for calculating the net health effects of research 
 
Guidance for gathering evidence to inform estimates of the value of research  
As shown above, a necessary part of any assessment of the value of research is formulating a view on 
the current level of uncertainty about the endpoints the research will examine. This uncertainty can 
be represented as a prior distribution. Evidence from existing studies including pilot studies or 
systematic reviews can be used to formulate priors. In practice, however, many research studies 
examine combinations of interventions and contexts which have not previously been studied. When 
                                                             
2 The expected health benefits (1,868) are not identical to the health benefits at the mean value of the 
endpoint (2,000) as the beta distribution used to describe the endpoint is not symmetrical. 
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evaluating a specific research proposal formally elicited expert opinion (11, 12) may therefore be 
valuable to complement quantitative and qualitative information to formulate priors.  
It is also necessary to estimate how the health benefits and additional costs of the programme 
change with the endpoint. Where a cost-effectiveness model is available this can be obtained by 
conducting one-way sensitivity analysis, i.e.,  varying the values taken by the endpoint of interest 
and recording the corresponding variations in health benefits and additional long-term costs 
associated with the intervention. If a cost-effectiveness model is not available for the context of 
interest, or existing models cannot be easily adapted, then formal expert elicitation can be used to 
quantify the magnitude of health benefits and additional costs at different levels of the endpoint.  
In order to estimate the net health effects of programmes we require an understanding of how 
additional programme costs translate to health opportunity costs. Recent work has estimated the 
opportunity cost of domestic health care spending in a wide range of low- and middle-income 
countries.(13) Where programmes are funded via overseas aid the opportunity costs of this funding 
will depend on the remit of the funder. An understanding of the potential health opportunity cost of 
an overseas aid funding stream can be garnered by reviewing the cost-effectiveness of those 
interventions that are and are not currently funded, and potentially developing a cost-effectiveness 
league table of funded programmes.  
Specification of each element described above is likely to require judgements regarding which 
evidence is relevant and how to use that evidence. By using the tool provided, users can explore the 
sensitivity of their results to each of these elements. In some contexts, the time-sensitive nature of a 
research-funding decision, analyst capacity, or funding availability, may make it infeasible to 
assemble these types of evidence. In these contexts, the tool can provide a quantitative basis for 
testing how different assumptions influence both the net DALYs averted by the research and the 
maximum amount a funder should be willing to spend on the research.  
We now show how the approach can be applied to a specific example. In this example evidence is 
available from a cost-effectiveness model but no probabilistic sensitivity analysis has been 
conducted thus prohibiting use of standard value of information methods. 
Self-testing example using the HIV synthesis model  
We show how these methods can be applied to assess the value of research in HIV self-testing 
programmes in Malawi. Self-testing programmes have been the subject of a number of recently 
published and ongoing research studies in sub-Saharan Africa (for some examples see (14-18)). We 
use the HIV synthesis model(19, 20) which has been used to assess the cost-effectiveness of a range 
of HIV prevention and treatment investments in different settings. The self-testing programme 
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under evaluation is not currently part of the HIV investment strategy. We assess two possible 
scenarios to estimate the population health benefits from research studies on self-testing 
programmes. Under the first scenario no research is conducted and investment in self-testing is 
based on current evidence about the costs and benefits of the programme. Under the second 
scenario research is commissioned and the results of the research inform the decision about 
investment in self-testing.   
Studies of HIV testing have included a range of endpoints measuring intervention effectiveness and 
costs at different points in the cascade of care. Frequently reported endpoints include coverage and 
uptake, HIV positivity, linkage and retention in care, and programme costs.(18)  The cost-
effectiveness of self-testing is strongly linked to the cost per new HIV diagnosis(21) which is 
calculated as the programme cost per person divided by the proportion of people diagnosed with 
HIV as a result of the programme. This suggests that two endpoints: programme costs and the 
proportion of people diagnosed with HIV, are likely to be important determinants of whether testing 
is cost-effective and therefore important targets for further research. The proportion of people 
diagnosed with HIV within facility-based care as a proportion of those targeted for testing reflects 
the combined effect of multiple endpoints collected within testing studies such as uptake, HIV 
positivity within those tested and linkage to facility-based care. We therefore examine a  cost study 
focused on the cost of the self-testing programme per individual eligible for testing; and an (ii) 
outcomes study estimating the proportion of the eligible population who are diagnosed with HIV in 
facility-based care. 
To evaluate the research proposals, we require priors describing the uncertainty about both 
programme costs and the proportion of the eligible population who are diagnosed with HIV in 
facility-based care. These priors will depend upon the characteristics of the target population and 
implementation setting, the details of the testing programme such as whether measures to enhance 
linkage are proposed (e.g. financial incentives, community-based support) and other contextual 
factors. The priors will therefore depend on the exact details of a specific research proposal and are 
most likely best formulated by combining available data, qualitative information and expert opinion. 
For the purposes of this demonstration we use only data from the literature to inform the priors. We 
use data from a systematic review and meta-analysis(18), focusing on those data relating to self-
testing. This work reflects the fairly limited data on self-testing available in 2015, when many of the 
self-testing studies were designed. For further details see Supplementary Material S1.  
Estimates of the additional costs and DALYs averted by a self-testing programme were derived from 
the HIV synthesis model. This is an individual-based stochastic model of heterosexual transmission, 
progression and treatment of HIV infection. We used outputs from the model generated by the 
12 
 
 “Working group on cost effectiveness of HIV testing in low income settings in sub-Saharan 
ĨƌŝĐĂ ?(21) which examined the effects of expanding HIV testing beyond a core testing programme 
considered to represent current standard of care in many countries. This core testing programme 
included testing for: pregnant women, symptomatic individuals, female sex workers (albeit that this 
is not fully implemented in many countries), and men coming forward for circumcision. This work 
examined the relationship between cost per HIV diagnosis and long-term cost effectiveness. The 
demographics of the population and the HIV epidemic features were based on those for Malawi and 
the model is calibrated to data that are representative of this setting. This work examined the cost-
effectiveness of testing for a wide range of scenarios. The scenarios reflect variation in the expanded 
testing programme testing rates, how well the programme targets HIV positive individuals and cost 
per test. The scenarios also reflect uncertainty about the context in which the programme is 
implemented in terms of the nature of the epidemic, ART programme characteristics, and the core 
testing programme. The model time horizon was 50 years and a discount rate of 3% wass used for 
costs and outcomes.  
We used the scenario analysis outputs from the model to estimate the relationship between costs 
and DALYs averted and both endpoints of interest (the proportion of the targeted population 
diagnosed with HIV in facility-based care, and programme costs). For further details see 
Supplementary Material S2. 
Estimating the net DALYs averted by self-testing, requires a measure of the health opportunity cost 
of the funds used to pay for self-testing. We have used a measure of opportunity cost of $500/DALY. 
This represents the cost per DALY averted of those services we expect to be displaced by 
investments in self-testing. $500/DALY is considered a relevant cost-effectiveness threshold for 
resource allocation within the HIV programme which is overwhelmingly reliant on overseas aid.(21, 
22) Additionally, HIV investments which Malawi and other countries in sub-Saharan Africa have 
struggled to scale up often have ICERs around $500/DALY, and HIV budgets have been shown to be 
exhausted in South Africa after funding interventions with ICERs around $500/DALY.(23) Where 
delivery of HIV interventions draws upon resources that would otherwise be used for non-HIV health 
activities a lower threshold is more appropriate, we return to this in the discussion.  
The analysis of the outputs from the HIV synthesis model were conducted in the statistical software 
R and associated packages.(24-39) 
RESULTS  
The implications of making decisions about the self-testing programme based on current evidence 
are shown in Table 1. The self-testing programme is cost-effective as indicated by the incremental 
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cost-effectiveness ratio (ICER) falling below the cost-effectiveness threshold of $500/DALY averted 
and positive values for net DALYs averted. These results represent the expected net health effects of 
the programme. However, due to uncertainties in the evidence base, there is a possibility that self-
testing is not cost-effective and in this case, implementing it will reduce net population health. 
Further research may therefore be of value to better understand the cost-effectiveness of the self-
testing programme. Figure 3 shows how the principles outlined in Figures 1-2 can be applied to 
quantify the implications of decision making based on further research on outcomes. The net DALYs 
averted by the self-testing programme increase as the proportion of people diagnosed with HIV 
increases (Figure 3 Panel A). At the mean value of the outcome endpoint, the programme delivers 
net health gains (108,400 averted DALYs). If the proportion of people diagnosed with HIV is less than 
the trigger point of 0.05, then self-testing is no longer cost-effective. The probability that the 
outcome endpoint is below this trigger value is shown by the shaded area in Figure 3 Panel B 
(probability of 0.33). If the outcome study is commissioned then this would avoid the programme 
being implemented in these circumstances. The avoided potential waste of health care resources 
can be translated into population health gain as indicated by the grey shaded area in Figure 3 Panel 
A. Weighting these gains from research (Figure 3 Panel A grey area) by the likelihood that the 
outcome endpoint takes these values (Figure 3 Panel B red bars) shows that research could 
potentially avert an additional 41,700 DALYs compared to implementation without research.  
 
Figure 3: Calculating the value of a study of self-testing in women and men focused on outcomes. 
Legend: Panel A shows the net health effects of the self- testing programme for different values of 
the outcome endpoint; Panel B shows the prior on the outcome endpoint. 
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The results of conducting this analysis for both the outcomes and cost endpoints are shown in Table 
1. The additional health benefits of research are 41,700 DALYs averted by the outcomes study and 
89,400 DALYs averted by the cost study. The maximum amount a research funder should be willing 
to spend is $20.9 million for the outcomes study and $44.7 million for the cost study, this suggests 
that further research is potentially valuable in this setting.  
 
Table 1: Population health consequences of implementation without and with additional research 
for the HIV self-testing case study 
Implications of decision making without further research      
Expected DALYs averted by programme  1,884,832 
Expected additional long-term costs associated with 
programme 
 
$888,203,454 
Expected health opportunity costs of funding programme  1,776,407 
Incremental cost-effectiveness ratio ($/DALY)  $471 
Expected net DALYs averted by implementation  108,425 
Implications of decision making informed by further research   Outcomes 
study 
 Cost study 
Value of endpoint at which decision changes1  0.052 $9.983 
Probability further research could change decision  0.33 0.33 
Expected net DALYs averted via research  41,740 89,375 
Potential maximum expenditure on study  $20,870,062 $44,687,606 
Total expected net DALYs averted  150,165 197,800 
1The units for this row are the proportion of the targeted population who are diagnosed with HIV in facility-
based care for the outcomes study and the cost per person tested in US$ for the cost study. 
2This indicates that expanded testing is no longer cost-effective if the proportion of the population who are 
diagnosed with HIV and linked to care is below 0.05. 
3This indicates that expanded testing is no longer cost-effective if the cost of testing exceeds $9.98 per 
individual eligible for testing. 
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So far we have shown how the population health benefits of research into self-testing can be 
quantified using existing models and model outputs and without use of advanced value of 
information methods. dŚŝƐĚŽĞƐŶ ?ƚĂŶƐǁĞƌĂŬĞǇƋƵĞƐƚŝŽŶĨĂĐŝŶŐŚĞĂůƚŚĐĂƌĞĚĞĐŝƐŝon makers, which 
is, when is the right time to implement a programme if we are uncertain about its net health effects?  
Three different policy choices are available to health care decision makers: 
Implementation without research: Implement programme without further research if current 
evidence indicates it is cost-effective. 
Implementation alongside research: Implement programme whilst conducting research, and 
consider scaling back programme if research shows programme does not improve net population 
health.  
Research then implementation: Delay decision about implementation until research reports. 
There are trade-offs to consider when choosing between these policies. If we wait until the research 
reports before implementing the programme, we forego the benefits of implementation in the 
meantime. On the other hand, if the programme is implemented whilst research is conducted there 
is a risk that the programme is found not to have been worthwhile once research findings emerge 
and is scaled back. This also risks the loss of resources where irrecoverable programme set-up costs 
are high. In some cases, implementation alongside research may not be feasible.  
We therefore quantified the net health consequences of each available choice open to policy 
makers, assuming the outcomes study takes 3 years to report and the cost study 1 year to report. 
This analysis reflects that under the research then implementation policy there will be no access to 
self-testing in the research period, and reflects that under both policies involving a research 
component, the benefits of research do not emerge until the research reports. The methods for this 
part of the analysis are shown in the supplementary material (see Supplementary Material S3) and 
results are shown in Table 2.  
Table 2: Population health consequences of implementation and research policy choices  
Implications of decision making without further research     
Expected net DALYs averted by implementation 108,425 
Implications of decision making informed by further research  Outcomes study  Cost study 
Implement testing programme alongside research    
Expected net DALYs averted via research 12,376 66,380 
Potential maximum expenditure on study $6,187,927 $33,189,959 
Total expected net DALYs averted 120,801 174,805 
Delay implementation until research reports    
Expected net DALYs averted via research -19,869 66,996  
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Potential maximum expenditure on study -$9,934,735 $33,497,945 
Total expected net DALYs averted 88,555 175,421 
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DISCUSSION 
In this paper we have shown how a graphical method can be used to estimate the value of research 
studies without knowledge of advanced value of information methods. We provide a simple excel 
tool to allow readers to use the method. Where time and resources allow, information from existing 
studies, expert elicitation, and outputs generated from existing cost-effectiveness models can be 
used. Where the assembly of such information is not feasible, the method and tool can be used to 
test how different assumptions influence estimates of the value of research, identify the 
assumptions under which a  proposed research study appears worthwhile, and allow decision 
makers to consider their plausibility.  These methods apply to a wide range of research studies 
aimed to inform programme design in the near-term (see Supplementary Material S4) and can be 
used to quantify the value of collecting data on different endpoints and in different populations. The 
methods are relevant where evidence is expected to be considered relevant for decision-making in 
multiple countries. The net health benefits of the research can be calculated for each country and 
considered collectively when assessing the value of the study.  
When evaluating a specific research proposal it may be important to consider, quantitatively or 
qualitatively, other factors that may modify the value of research. These include future changes that 
would modify the net DALYs averted by the intervention (e.g. anticipated price reductions for health 
technologies), uncertainty around whether the research completes and is used to inform decisions, 
the degree to which uncertainty is reduced, and the potential for the study to generate additional 
secondary outcome data which may be used in a range of ways.(4) In this example we assumed the 
research study was small relative to the population that will benefit from the research and did not 
therefore account for the benefits of self-testing for those enrolled in the study. In some contexts 
the population health benefits for this group are significant (e.g. in the case of large studies) and 
could be included in the calculations.(40) 
 
Findings from the HIV self-testing case study 
We applied the graphical method to a case study of HIV self-testing. This allowed us to show how 
existing evidence can be used to inform an assessment of the value of a future study, and how an 
assessment of the value of further research can be used to guide policy decisions relating to 
programme implementation and research.  
This showed that a one-year cost study is likely to be of high value, whereas a three-year outcomes 
study offered more modest value. The outcomes study is only worth conducting if it is run in parallel 
with implementation. Delaying implementation until the outcomes study is complete results in 
18 
 
worse outcomes than implementing self-testing without further research. Overall the results suggest 
that if a decision maker considered set-up costs to be significant, they may wish to commission a 
cost study and delay implementation of self-testing until it reports. If set-up costs are not considered 
significant, running a cost and outcomes study alongside implementation may be the preferred 
option.  
The value of research is fundamentally an economic question, as research that aims to inform 
programme design can only deliver value if there is a chance that its results could change the 
assessment about whĞƚŚĞƌĂƉƌŽŐƌĂŵŵĞ ?ƐďĞŶĞĨŝƚƐŽƵƚǁĞŝŐŚthe opportunity costs. The cost per 
DALY averted threshold used to determine the health opportunity costs imposed by programme 
costs is a key driver of this assessment. We used a value of $500/DALY to reflect the opportunity 
cost of HIV service funding. This value is subject to uncertainty and our conclusions will differ if a 
different estimate of opportunity cost is used. This emphasises the need for both resource allocation 
and research prioritisation decisions to be based on a robust assessment of the opportunity cost of 
health care funds. Recent work has estimated the cost per DALY averted for general (i.e. not HIV 
specific) health care spending in a range of countries.(13) Using the estimate generated for Malawi 
of $138/DALY(13) within our analysis results in research no longer generating value. The health 
opportunity costs of dedicating funding to the self-testing programme become so high that even 
under optimistic scenarios about the outcomes and costs of testing, the programme will not produce 
positive net population health benefits.  This may become relevant as funding of HIV services 
becomes more reliant on domestic rather than overseas funding. 
The estimates presented reflect the impact of the self-testing studies for population health in 
Malawi.  It is possible that the research could be used to inform resource allocation decisions in 
additional countries with similar local epidemiology and health-care seeking behaviours. If this is the 
case we will underestimate the value of the studies. Where a research study is expected to be used 
in a number of countries the approach described above can be extended to reflect the total global 
value of the research. The value of the study in each country can be estimated accounting for 
differences in the size of the population that stand to benefit from research, the costs and health 
benefits of the intervention and the cost-effectiveness threshold. This will generate estimate of the 
value of research in each country which can then be aggregated to estimate the global value of 
research.(4, 41) A worked example of this is provided in Woods et al.(42)  
 
Using estimates of the net DALYs averted by research to inform research prioritisation  
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Using estimates of the net DALYs averted by research to inform research prioritisation as suggested 
here is likely to require substantive changes to how evidence is used to support research funding 
decisions.  
Currently, research funding decisions do not routinely use the type of evidence discussed in this 
paper. Institutional changes are required to facilitate use of the methods. This could include 
requiring funding bids to include these types of analyses, funders themselves conducting the 
analyses for submitted research bids, or decision makers within LMICs conducting analyses to inform 
the specification of research calls. Research to explore how this might work in practise is ongoing in 
high-income settings(2, 6, 43) and further work to assess this in LMICs is warranted.  
Our case study focused on HIV where both evidence and detailed cost-effectiveness models are 
often well-developed. In many contexts, models used to assess cost-effectiveness will be available 
and can be used and extended to make the value of information assessments described here. For 
decisions where available evidence is sparse, cost-effectiveness analyses unavailable, or collation of 
such evidence is not feasible, our work can be used to test the sensitivity of the value of research to 
different plausible assumptions. This may be sufficient to determine whether research should be 
funded. If decisions about research appear sensitive to different plausible assumptions then there 
may be value in low-level initial research funding to assemble existing evidence, conduct expert 
elicitation and develop basic cost-effectiveness analysis and make a more informed assessment of 
the value of research.   
The robustness of any estimates of value of information will depend on the use of appropriate priors 
to represent uncertainties in the available evidence, the credibility of the underlying cost-
effectiveness model, and use of an appropriate measure of health opportunity costs. Specification of 
each element is likely to require judgements regarding approach and input parameters. By using 
quantitative methods such as those set out here, the judgements are open to empirical challenge 
thus allowing for more accountable decision making. When cost-effectiveness analyses are used to 
support service investments this often involves an iterative process whereby relevant stakeholders 
review key judgements, and scenarios are presented exploring the implications of different 
judgements. We envisage a similar deliberative decision-making process could be usefully 
implemented when using value of information estimates to inform research prioritisation.  
Ultimately, once an assessment of the potential population health benefits of a research study has 
been made, a research funder will have to assess whether the value offered by research proposals is 
sufficient to justify the opportunity costs imposed by funding the research. These opportunity costs 
depend on potential alternative uses for those research funds which may include other research and 
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non-research investments. This raises the question of how the research funder should assess the 
opportunity costs of their research funds when prioritising between funding applications. One way 
of doing this is to ensure only those proposals with the lowest research cost per net DALY averted 
are funded i.e. a cost-effectiveness league table approach for research proposals. The net DALYs 
averted by research estimated using the methods presented here could be used alongside the 
research costs to generate this information. In the absence of this evidence, a useful but imperfect 
starting point is to assume that the opportunity cost of research funds and service funds is similar. 
We have used this assumption within this work to estimate the maximum a research funder should 
be willing to spend on a study. Where research costs are known this assumption can be used to 
translate research costs to health opportunity costs which can be directly compared to the net 
health benefits of research. Those proposals offering the largest different between net health 
benefits of research and health opportunity costs of research funding may be considered particularly 
attractive to research funders.  
 
CONCLUSION  
Our work provides a method for estimating the health benefits of research in a practical and timely 
fashion. This can be used to prioritise funding of those research and evidence generation activities 
that offer real potential to improve population health. 
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Supplementary material 
S1 Priors for study endpoints 
The prior for the proportion of the targeted population linked to and diagnosed within facility-based 
care was based on a systematic review and meta-analysis by Sharma et al.(18) This looked at a wide 
range of HIV testing approaches in sub-Saharan Africa. Analyses restricted to self-testing were used 
where available. The systematic review provided data for three related endpoints: uptake which is 
calculated as the proportion tested of those offered testing, HIV positivity which is calculated as the 
number of individuals testing HIV positive of those tested, and the proportion linked to facility-based 
care of those who tested positive (we assume that all of these individuals will then be diagnosed 
with HIV). Estimates of the mean for each endpoint, and the associated confidence intervals, are 
presented in Table S1. A beta distribution was used to represent the prior for each endpoint.(44) The 
standard errors for the distributions were doubled to reflect the additional uncertainty inherent in 
generalising data from the literature to a future specific study setting. The overall prior for the 
proportion of the targeted population ultimately linked to and diagnosed within facility based care 
was then estimated by randomly sampling from each beta distribution and multiplying the three 
sampled proportions.  
 
Table S1: Data used to inform prior for the proportion of the targeted population linked to facility-
based care 
Parameter Proportion: 
Mean (95% confidence interval) 
Notes on source 
Uptake 0.69 (0.59-0.78) Random effects meta-analysis of home self-
testing studies from Sharma et al. Reflects two 
studies conducted in Malawi including three 
study arms. 
HIV positivity 0.09 (0.08-0.10) Restricted to facilitated linkage study arm as 
most studies of self-testing are now focused on 
introducing some form of enhanced linkage, 
and this is expected to impact on reporting of 
positive HIV test results. 
Proportion linked to facility-
based care 
0.95 (0.87-0.98) Endpoint not reported for self-testing studies. 
Data instead reflect home-based and campaign 
community testing with counselling and 
facilitated linkage.  
 
In 2014/15, when a number of self-testing studies were being designed, there was very limited data 
relating to costs for self-testing programmes. The review by Sharma et al. did not identify any 
costing studies for self-testing but did report costing data for home-based community HIV testing 
31 
 
and counselling. These estimates ranged from $7.2 to $14.65 per person tested (data in 2012 USD 
and collected in Kenya, Malawi, Swaziland and Uganda).  We assumed that given the potential 
savings in time from self-testing that $15 represented an appropriate upper bound on testing, and 
$3 per person represented an appropriate lower bound. We therefore used a gamma distribution 
with mean $9 and confidence interval $3-15 for the cost of the self-testing programme per individual 
targeted for testing. 
 
S2 Estimating the relationship between net DALYs averted and key endpoints 
The relationship between net DALYs averted and the cost and outcome endpoints were informed by 
existing scenario analysis of the HIV synthesis model. We included in our analysis those scenarios 
modelled by the HIV synthesis model which are representative of the situation in Malawi. This was 
achieved by selecting scenarios where the calibration scores indicated sufficient agreement between 
the model predictions and key data on the Malawian context.  
The existing scenario analyses were used as the basis for this work. An alternative approach would 
have been to run additional scenarios which better fitted our purpose (e.g. one-way sensitivity 
analyses examining the impacts of the cost and outcomes endpoints). Although this would have 
simplified our work this would have created additional burden for the HIV synthesis modelling team 
due to the large amount of analyst and computational time taken to run the model.    
Regressions were developed using the scenario analysis from the HIV synthesis model as data. These 
regressions used the scenario analysis outputs to predict DALYs averted by expanded testing and 
total costs incurred by expanded testing (compared to the standard of care core testing) as a 
function of the endpoints of interest. The regression analysis for DALYs averted included the 
proportion of the targeted population who are diagnosed with HIV in facility-based care in year 0-3 
(the outcome endpoint) as an independent variable. The regression analysis for total costs incurred 
included both the outcome endpoint, and programme cost per targeted individual (the cost 
endpoint) as independent variables. Regression models were fitted that allowed DALYs and total 
costs to be a non-linear function of the endpoints and that allowed the endpoints to interact. 
Constraints were imposed on the regressions so that DALYs averted must increase with the outcome 
endpoint, and costs incurred must increase with this endpoint and the cost endpoint. These 
constraints are in recognition of some residual stochastic variation in the model simulation outputs 
and avoid the flexible model used over-fitting to individual scenario results and producing 
implausible results. The analysis used the Shape Constrained Additive Models package in R.(25) 
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There was wide variation across testing scenarios in the number of individuals targeted for testing 
i.e. the scale of the testing programme.  This reflects the objective of the original analysis which 
aimed to explore a wide range of testing programmes with different characteristics. Across 
scenarios, variation in programme scale was correlated with the outcome endpoint. This was 
intended to reflect that smaller programmes are often expected to have higher yields of HIV positive 
individuals (e.g. partner testing). Uncertainty in the size of the target population is not however 
something we expected to address via the cost or outcome studies we are evaluating. We therefore 
rescaled the total population DALYs and total costs to per capita values prior to conducting the 
regression analysis.  
The regression analysis allowed direct prediction of the DALYs averted and total costs incurred per 
capita for different values of the endpoints of interest. Predictions were made for 1,000 values 
simulated from the prior for the outcome endpoint and 1,000 values from the prior for the cost 
endpoint. Predictions of DALYs averted and total costs incurred were used alongside the estimate of 
the cost-effectiveness threshold to estimate net DALYs averted by self-testing compared to the core 
testing programme for different values of the endpoints.  
To estimate the value of the outcomes study we required an estimate of net DALYs averted for each 
value of the outcome endpoint. This was calculated by taking each value of the prior for this 
endpoint, and then averaging the net DALYs averted across the values for the prior for the cost 
endpoint. This averaging reflects the fact that if we run an outcomes study the cost endpoint will 
remain uncertain. The resulting information on the relationship between the outcome endpoint and 
net DALYs averted was then used alongside the prior for the outcome endpoint to estimate the 
value of the outcome study as shown in the main manuscript (see Figure 1 and surrounding text). An 
equivalent process was followed to estimate the value of the cost study. Expected outcomes in the 
absence of further research were calculated by average DALYs averted and additional costs across 
values of the endpoints. This ensures that the estimates underpinning the analysis of decision 
making without further research are the same as the estimates underpinning the analysis of decision 
making informed by further research.   
The per capita estimates of net DALYs averted by research were then rescaled to reflect the average 
population eligible for the testing programme from the HIV synthesis model. This was calculated by 
fitting a polynomial describing the relationship between the population eligible for testing and the 
outcome endpoint. The predicted population size was then generated for each value of the outcome 
endpoint sampled from the prior. These values were then averaged to calculate the average eligible 
population. 
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S3 Impact on net DALYs averted by research of delaying implementation until research reports or 
implementation alongside research 
Implementation alongside research  
When a programme is expected to be cost-effective based on currently available evidence, a 
decision maker may consider implementing the programme whilst the research is conducted. This 
allows the expected benefits of implementation to accrue whilst the research is being conducted. 
From the point that research is reported, if research supports continued investment in the 
intervention the benefits and costs continue to accrue for the remainder of the model time horizon. 
If the research shows the programme is not cost-effective then the programme can be cancelled to 
avoid further negative impacts on net population health. For example, if research takes 3 years to 
report the expected benefits of implementation accrue over years 0-3 and the benefits of research 
accrue over years 3-50.   
These principles are reflected in the analysis by running two sets of regressions to predict DALYs 
averted and costs incurred:  
(1) analyses for full model time horizon of 50 years; and  
(2) analyses removing those benefits or costs accrued during the initial research period of 1 or 3 
years, depending on the study.  
The difference between the expected net DALYs averted using regression set (1) and the expected 
net DALYs averted using regression set (2) can be used to calculate the expected net DALYs averted 
by implementation during the 1- or 3-year research period. The results from analysis (2) can be used 
to calculate the value of implementation informed by research and will reflect the value from the 
point that research reports up to the model time horizon. The sum of these two components 
represents the total net health effects of the implementation alongside research policy.  
The scenarios from the HIV synthesis model reflect two possible situations, implementation of 
additional testing or continue with standard of care core testing. Under the implementation 
alongside research scenario we have a third situation where testing may be implemented for 1 or 3 
years during research but then cancelled if the research does not support continued 
implementation. We did not have access to an analysis modelling the implications of this and 
therefore assumed that there were no further consequences of self-testing beyond years 1 or 3 in 
those scenarios where the self-testing programme was discontinued.  This is a simplification as there 
may be costs associated with winding down the programme and the costs and health benefits for 
those diagnosed during the research period will continue to accrue beyond this period. For further 
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of discussion of this issue and potential additional analyses that could be conducted see Woods et 
al.(42)  
 
Research then implementation  
Health care decision makers may choose to wait until they know the results of research before 
implementing the programme. This delay will affect the net DALYs we can expect to avert by using 
the research to make more informed decisions. When implementation is delayed until research 
reports the intervention delivers no benefit (outside of the research population) until research 
reports. The net DALYs averted by research therefore accrue over a shorter time horizon than the 
full 50 year model time horizon. This is reflected in the analysis by reducing the time horizon of the 
model by the duration of the research (1 year for costing research, 3 years for outcomes). The net 
DALYs averted and total costs incurred under each scenario were therefore computed using a 47 
year and a 49 year time horizon as well as a 50 year time horizon. The value of research could then 
be computed using these revised figures within the regression and subsequent analyses described in 
section S2. The resulting value of research was then subjected to additional discounting to reflect 
the fact that beneficiaries of the intervention would now have to wait an additional 1-3 years to 
receive it.  
 
Approach for settings where disease dynamics are not considered relevant 
The approach described above applies to a population-level model that reflects use of a programme 
over time. These types of model are often used where disease dynamics are considered an 
important determinant of the impacts of interventions.  
An alternative, simpler, approach can be used where it is considered appropriate to characterise the 
impact of interventions at the individual or cohort level without consideration of disease dynamics. 
This is typically the case for non-communicable diseases, or interventions that are used in the 
context of infectious diseases but are not expected to modify disease dynamics. In such ĐŽŶƚĞǆƚ ?Ɛ 
individual-level estimates of net health effects can be rescaled to reflect use of an intervention in 
different numbers of individuals in a population or over time.  
To illustrate this, we use a numeric example where 1,000 people per year are eligible for the 
intervention and the intervention will be used for the next 20 years, we also assume a discount rate 
of 3%. From the tool we can calculate the per capita net DALYs averted when decisions are made 
based on current evidence and when further research is used to support decision making. We 
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assume this has been done and shows that under current evidence implementation would result in 
an expected gain of 1 net DALY averted per capita and that decision making informed by further 
research would generate an expected 1.5 net DALYs per capita. We also assume research takes 5 
years to report. To generate the outcomes of each policy (implementation without research, 
implementation alongside research and research then implementation) we proceed as shown in 
Table S2.  
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Table S2: Estimating the overall population health implications of implementation without research, 
implementation alongside research and research then implementation 
 Undiscounted net DALYs averted Discounted net DALYs averted 
Year Implementation 
without research 
Implementation 
alongside research 
Research then 
implementation 
Implementation 
without research 
Implementation 
alongside research 
Research then 
implementation 
1                                         
1,000  
                                           
1,000  
                                    
-    
                                           
1,000  
                                        
1,000  
                                    
-    
2                                         
1,000  
                                           
1,000  
                                    
-    
                                           
971  
                                        
971  
                                    
-    
3                                         
1,000  
                                           
1,000  
                                    
-    
                                           
943  
                                        
943  
                                    
-    
4                                         
1,000  
                                           
1,000  
                                    
-    
                                           
915  
                                        
915  
                                    
-    
5                                         
1,000  
                                           
1,000  
                                    
-    
                                           
888  
                                        
888  
                                    
-    
6                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
863  
                                        
1,294  
                                    
1,294  
7                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
837  
                                        
1,256  
                                    
1,256  
8                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
813  
                                        
1,220  
                                    
1,220  
9                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
789  
                                        
1,184  
                                    
1,184  
10                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
766  
                                        
1,150  
                                    
1,150  
11                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
744  
                                        
1,116  
                                    
1,116  
12                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
722  
                                        
1,084  
                                    
1,084  
13                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
701  
                                        
1,052  
                                    
1,052  
14                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
681  
                                        
1,021  
                                    
1,021  
15                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
661  
                                        
992  
                                    
992  
16                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
642  
                                        
963  
                                    
963  
17                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
623  
                                        
935  
                                    
935  
18                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
605  
                                        
908  
                                    
908  
19                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
587  
                                        
881  
                                    
881  
20                                         
1,000  
                                           
1,500  
                                    
1,500  
                                           
570  
                                        
855  
                                    
855  
Total                                         
20,000  
                                           
27,500  
                                    
22,500  
                                           
15,324  
                                        
20,627  
                                    
15,910  
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S4 Research studies informing programme design and resource allocation 
Table S3 shows the range of studies to which the methods presented can be applied, and provides 
information on some of the funders who support these studies and who may therefore be interested 
in quantitative assessments of their health effects. The table also indicates the potential 
generalizability of different types of studies. This will have implications for the extent to which there 
is a need to assess the health benefits of the studies in different countries and aggregate total value 
across countries.  
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Table S3: Research and evidence generation activities to support HIV treatment and prevention programmes that could be evaluated using these methods  
Types of studies Example outputs used to inform decision making Expected 
generalisability of 
research across 
settings 
Example funders 
Phase III-IV clinical trials of 
medical interventions (drugs, 
diagnostics, vaccines) 
x Effectiveness, e.g., in terms of individual health outcomes or acquisition 
of HIV; 
x Measures of feasibility and cost of service implementation 
High or medium European & Developing Countries Clinical Trials 
Partnership (EDCTP)  
UK Medical Research Council (MRC) 
Wellcome Trust 
US National Institutes of Health (NIH) 
 
Implementation studies x Impact of alternative models of delivery of care on programme 
engagement and costs in different populations and geographies. 
Low or medium US NIH Fogarty International Center 
Population Council 
President's Emergency Plan for AIDS Relief (PEPFAR) 
U.S. Agency for International Development (USAID) 
Bill and Melinda Gates Foundation 
Epidemiological studies 
including surveillance studies 
and longitudinal follow-up 
x Prevalence and incidence of HIV and their variation across time, place 
and subpopulations; 
x Behavioural surveillance measures (e.g. number and nature of sexual 
partners, use of condoms); 
x Programmatic data on number of individuals receiving specific 
treatments or prophylaxis; 
x Response to antiretroviral therapy (viral load, CD4 counts, resistance), 
rates of clinical events, including mortality, rate of loss to follow-up and 
re-engagement in care, and how these vary across geographies and 
subpopulations (defined by socioeconomic status, disease features, 
urban/rural etc.). 
Low or medium Nationally funded programme monitoring and 
surveillance data.   
USAID (funds Demographic and Health Surveys, DHS, 
alongside other international and national funders) 
US Centers for Disease Control and Prevention (CDC) 
(funds Population-based HIV Impact Assessments 
(PHIA) surveys)  
UK MRC 
UK Department for International Development  
Wellcome Trust 
Bill and Melinda Gates Foundation 
 
Resource use and cost 
studies 
x Programme costs and how these vary across geographies, by 
subpopulation, by programme scale, and by service delivery modalities. 
May be integrated into trials or implementation studies. 
x Costs of long-term disease management.  
 
Low Bill and Melinda Gates Foundation 
 
User perspectives and 
preferences including 
morbidity surveys 
x Disability weights (for computation of disability-adjusted life years, 
DALYs or quality-adjusted life years, QALYs) 
x Out of pocked and indirect costs of health care use 
Low Bill and Melinda Gates Foundation 
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